Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma.
de Sousa LG, Neto FL, Lin J, Ferrarotto R. de Sousa LG, et al. Among authors: ferrarotto r. Curr Oncol Rep. 2022 May;24(5):621-631. doi: 10.1007/s11912-022-01233-z. Epub 2022 Feb 25. Curr Oncol Rep. 2022. PMID: 35212920 Review.
Lung-MAP--framework, overview, and design principles.
Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Ferrarotto R, et al. Chin Clin Oncol. 2015 Sep;4(3):36. doi: 10.3978/j.issn.2304-3865.2015.09.02. Chin Clin Oncol. 2015. PMID: 26408303 Free article. Review.
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Ferrarotto R, et al. J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21. J Clin Oncol. 2017. PMID: 27870570 Free PMC article.
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer.
Kamal M, Ng SP, Eraj SA, Rock CD, Pham B, Messer JA, Garden AS, Morrison WH, Phan J, Frank SJ, El-Naggar AK, Johnson JM, Ginsberg LE, Ferrarotto R, Lewin JS, Hutcheson KA, Cardenas CE, Zafereo ME, Lai SY, Hessel AC, Weber RS, Gunn GB, Fuller CD, Mohamed ASR, Rosenthal DI. Kamal M, et al. Among authors: ferrarotto r. Oral Oncol. 2018 Apr;79:1-8. doi: 10.1016/j.oraloncology.2018.01.025. Epub 2018 Feb 10. Oral Oncol. 2018. PMID: 29598944 Free PMC article.
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R, William WN Jr, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS. Ferrarotto R, et al. Oral Oncol. 2018 Jul;82:83-90. doi: 10.1016/j.oraloncology.2018.05.014. Epub 2018 May 19. Oral Oncol. 2018. PMID: 29909907 Clinical Trial.
182 results